Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLL | Q9UGP5 | 7/20 | 0.72 |
| ▸ | STAT1 | P42224 | 1/20 | 0.72 |
| ▸ | MET | P08581 | 7/20 | 0.69 |
| ▸ | SIRT2 | Q8IXJ6 | 4/20 | 0.66 |
| ▸ | SIRT1 | Q96EB6 | 4/20 | 0.66 |
| ▸ | EP300 | Q09472 | 3/20 | 0.56 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.56 |
| ▸ | PTGES | O14684 | 2/20 | 0.50 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | DLAT | P10515 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 6-Epi-Guttiferone J SCHEMBL31292810 | 1.00 | POLL (0.72) | POLLSTAT1METSIRT2SIRT1 | |
| Guttiferone A SCHEMBL12634388 | 1.00 | POLL (0.72) | POLLSTAT1METSIRT2SIRT1 | |
| Guttiferone K SCHEMBL31345834 | 1.00 | POLL (0.72) | POLLSTAT1METSIRT2SIRT1 | |
| Guttiferone P SCHEMBL31345812 | 0.96 | MET (0.74) | POLLSTAT1METSIRT2SIRT1 | |
| SCHEMBL21710405 | 0.96 | POLL (0.68) | POLLSTAT1METSIRT2SIRT1 | |
| Guttiferone I SCHEMBL31238109 | 0.95 | MET (0.77) | POLLSTAT1METSIRT2SIRT1 | |
| Aristophenone A SCHEMBL31345818 | 0.89 | EP300 (0.69) | POLLSTAT1METSIRT2SIRT1 | |
| Guttiferone L SCHEMBL31345836 | 0.88 | POLL (0.60) | POLLSTAT1METSIRT2SIRT1 | |
| Guttiferone O SCHEMBL31345820 | 0.87 | MET (0.61) | POLLSTAT1METSIRT2SIRT1 | |
| Guttiferone B SCHEMBL31345806 | 0.86 | MET (0.65) | POLLSTAT1METSIRT2SIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025024478-A1 | COMPOSITIONS FOR THE MODULATION OF TASTE | IXORA SCIENTIFIC INC. (US) | 2025-01-30 | — | — | WO | claimed |
| CN-108601805-B | Bioactive composition from ajuga apiacea and method of making same | ISP投资有限公司 | 2022-08-09 | — | — | CN | claimed |
| EP-3386525-B1 | BIOACTIVE COMPOSITIONS FROM ACHACHAIRU (GARCINIA HUMILIS) AND METHODS FOR THEIR PRODUCTION | ISP INVESTMENTS LLC (US) | 2022-02-16 | — | — | EP | claimed |
| US-11000056-B2 | Bioactive serum fraction from achachairu (Garcinia humilis) which is free of benzophenone and proteins | ISP INVESTMENTS LLC (US) | 2021-05-11 | — | — | US | claimed |
| US-20200046006-A1 | BIOACTIVE COMPOSITIONS FROM ACHACHAIRU (GARCINIA HUMILIS) AND METHODS FOR THEIR PRODUCTION | ISP INVESTMENTS LLC (US) | 2020-02-13 | — | — | US | claimed |
| EP-3386525-A1 | BIOACTIVE COMPOSITIONS FROM ACHACHAIRU (GARCINIA HUMILIS) AND METHODS FOR THEIR PRODUCTION | ISP Investments LLC (US) | 2018-10-17 | — | — | EP | claimed |
| CN-108601805-A | Exactly from Ah（Gold mangosteen）Bioactive composition and preparation method thereof | ISP投资有限公司 | 2018-09-28 | — | — | CN | claimed |
| WO-2017100430-A1 | BIOACTIVE COMPOSITIONS FROM ACHACHAIRU (GARCINIA HUMILIS) AND METHODS FOR THEIR PRODUCTION | ISP INVESTMENTS LLC (US) | 2017-06-15 | — | — | WO | claimed |
| CN-104224764-A | Application of caulis flavone A in preparation of anti-HIV drug | NANJING BIAOKE BIO TECHNOLOGY CO LTD | 2014-12-24 | — | — | CN | claimed |
| WO-2025024478-A1 | COMPOSITIONS FOR THE MODULATION OF TASTE | IXORA SCIENTIFIC INC. (US) | 2025-01-30 | — | — | WO | disclosed |
| WO-2024226703-A2 | ASYMMETRIC SYNTHESIS AND DIVERSIFICATION OF A STABILIZED SALVINORIN A SCAFFOLD | THE SCRIPPS RESEARCH INSTITUTE (US) | 2024-10-31 | — | — | WO | disclosed |
| WO-2024189607-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT | DIDENKO KIRILL (MX) | 2024-09-19 | — | — | WO | disclosed |
| US-20240269106-A1 | SMALL MOLECULE MODULATOR TARGETING A RARE HISTONE MODIFICATION REGULATING ADIPOGENESIS AND PHARMACEUTICAL FORMULATION THEREOF | COUNCIL OF SCIENT AND INDUSTRIAL RESEARCH AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGN (IN) | 2024-08-15 | — | — | US | disclosed |
| EP-4346786-A1 | SMALL MOLECULE MODULATOR TARGETING A RARE HISTONE MODIFICATION REGULATING ADIPOGENESIS AND PHARMACEUTICAL FORMULATION THEREOF | Council of Scientific and Industrial Research, an Indian Registered Body Incorporated under Regn. of Soc. Act (Act XXI of 1860) (IN) | 2024-04-10 | — | — | EP | disclosed |
| US-20100015262-A1 | NOVEL USE OF COMPOUNDS AND COMBINATIONS OF COMPOUNDS FOR IMPROVING THE PHYSICAL APPEARANCE | DSM IP ASSETS B.V. (NL) | 2010-01-21 | — | — | US | disclosed |
| EP-2070543-A1 | High-efficiency procedure for preparing standarized hydroalcoholic propolis extract | Bios Line S.p.a. (IT) | 2009-06-17 | — | — | EP | disclosed |
| EP-2001561-A2 | NOVEL USE OF COMPOUNDS AND COMBINATIONS OF COMPUNDS FOR IMPROVING THE PHYSICAL APPEARANCE | DSMIP Assets B.V. (NL) | 2008-12-17 | — | — | EP | disclosed |
| WO-2008119070-A1 | METHODS OF TREATMENT USING SIRT MODULATORS AND COMPOSITIONS CONTAINING SIRT1 MODULATORS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008082646-A2 | HISTONE DEACETYLASE INHIBITORS, COMBINATION THERAPIES AND METHODS OF USE | THE JOHNS HOPKINS UNIVERSITY (US) | 2008-07-10 | — | — | WO | disclosed |
| WO-2007112996-A2 | NOVEL USE OF COMPOUNDS AND COMBINATIONS OF COMPUNDS FOR IMPROVING THE PHYSICAL APPEARANCE | DSM IP ASSETS B.V. (NL) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11000056-B2 | Bioactive serum fraction from achachairu (Garcinia humilis) which is free of benzophenone and proteins | SHBG, IGFBP6, ALPL | POLL 3574/4885STAT1 2144/4885MET 2186/4885 |
| US-20200046006-A1 | BIOACTIVE COMPOSITIONS FROM ACHACHAIRU (GARCINIA HUMILIS) AND METHODS FOR THEIR PRODUCTION | BRAP, SHBG, ALPL | POLL 3183/4885STAT1 2864/4885MET 2490/4885 |
| US-20240269106-A1 | SMALL MOLECULE MODULATOR TARGETING A RARE HISTONE MODIFICATION REGULATING ADIPOGENESIS AND PHARMACEUTICAL FORMULATION THEREOF | EP300, HDAC1, HDAC3 | POLL 4870/4885STAT1 1634/4885MET 1101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.